Dr. Sato has over 13 years of drug discovery and antibody engineering experience.. Before Sutro, he was Sr. Director of Antibody Engineering at OncoMed Pharmaceuticals, where he was responsible for all human antibody lead discovery and engineering. He served as project team leader on several key antibody projects through IND filing, one of which. entered the clinic early last year (OMP-59R5).. Before OncoMed, Dr. Sato was Sr. Director of Lead Discovery at Dyax Corp. and was responsible for antibody, peptide, and small protein discovery using their proprietary phage display technology. In this role, he also oversaw external alliances with major pharmaceutical, imaging, and biotechnology partners.. He obtained his doctorate degree from MIT working in the lab of Dr. Lawrence J. Stern, where he studied MHC class II structure-function relationships.
